IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) reported a meaningful turnaround in its fourth quarter 2024, capping a year of repositioning with 25% revenue growth and its first quarterly adjusted EBITDA profit in recent history.
The medical cannabis company, which is jointly headquartered in Canada and Israel, generated C$13.3 million in…
Please login to read all 451 words.
